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Abstract
Background: Proliferation of the vasa vasorum has been implicated in the pathogenesis of atherosclerosis, and
the vasa vasorum is closely associated with resident stem cells within the vasculature. C-reactive protein (CRP)
is positively correlated with cardiovascular disease risk, and our previous study demonstrated that it induces
inflammatory reactions of perivascular adipose tissue by targeting adipocytes.
Methods: Here we investigated whether CRP affected the proliferation and proangiogenic paracrine activity
of adipose-derived stem cells (ADSCs), which may contribute to vasa vasorum angiogenesis.
Results: We found that CRP did not affect ADSC apoptosis, cell cycle, or proliferation but did increase their
migration by activating the PI3K/Akt pathway. Our results demonstrated that CRP can upregulate vascular
endothelial growth factor-A (VEGF-A) expression by activating hypoxia inducible factor-1α (HIF-1α) in ADSCs,
which significantly increased tube formation on Matrigel and functional vessels in the Matrigel plug
angiogenesis assay. The inhibition of CRP-activated phosphorylation of ERK and Akt can suppress CRP-
stimulated HIF-1α activation and VEGF-A expression. CRP can also stimulate proteolytic activity of matrix
metalloproteinase-2 in ADSCs. Furthermore, CRP binds activating CD64 on ADSCs, rather than CD16/32.
Conclusion: Our findings implicate that CRP might play a role in vasa vasorum growth by activating the
proangiogenic activity of ADSCs.
Keywords: C-reactive protein, Angiogenesis, Adipose-deprived stem cell, Vascular endothelial growth factor,
Hypoxia-inducible factor-1α
Background
C-reactive protein (CRP), an acute-phase protein and a
member of the pentraxin family, members of which are
characterized by a cyclic pentameric structure, exhibits
Ca2+-dependent binding to ligands and binds to the
membrane of injured cells as well as the membrane and
nuclear components of necrotic and apoptotic cells [1].
Baseline circulating concentrations of CRP are signifi-
cantly associated with cardiovascular disease risk in the
general population [2]. Recent clinical trials and basic
research demonstrated that CRP could be a proathe-
rogenic factor for atherosclerosis [3], whereas in-vitro
experiments reported that CRP preparations had been
contaminated by bacterial products or other contami-
nated preparations [4, 5], and a recent study showed that
no proinflammatory cytokines or acute phase proteins
were detected after purified CRP from pooled normal
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human donor plasma was infused into seven healthy adult
human volunteers [6]. All evidence indicates that the func-
tions of CRP still remain controversial as a biomarker or
mediator.
Research into the pathogenesis of atherosclerosis has
focused historically on the intima and media. However,
recent studies demonstrated that adventitial vasa vasorum
angiogenesis and periadventitial adipose tissue inflamma-
tion play an important role in the development of coronary
atherosclerosis, known as the “outside-in” phenomenon
[7, 8]. Manka et al. [9] reported that the transplantation of
perivascular adipose tissue (PVAT) from donor mice to
the carotid arteries can promote vasa vasorum neovas-
cularization in the adventitia, indicating that PVAT
inflammation played a role in adventitia vasa vasorum
angiogenesis. A certain amount of mesenchymal stem
cells within adipose tissue, including PVAT [10], were
closely associated with new vessel angiogenesis [11]. Stem
cells are thought to be quiescent or to cycle slowly under
normal circumstances, and the biological function of stem
cells is activated by microenvironmental reactions such as
inflammation, hypoxia, and oxidative stress. Whether
PVAT inflammation could promote mesenchymal stem
cell-induced vasa vasorum angiogenesis is not clearly
understood.
PVAT inflammation is often accompanied by increased
circulating CRPs. Because we know that the imbalance of
adiponectin and leptin is the main cause of adipose tissue
inflammation, increased leptin is able to further promote
CRP production from hepatocytes and endothelial cells
[12]. It is therefore interesting to investigate the role of
CRP in PVAT inflammation. Our previous study showed
that CRP could activate inflammatory reactions within
PVAT by stimulating cultured adipocytes to release tumor
necrosis factor alpha, interleukin-6, and monocyte chemo-
attractant protein-1 (MCP-1) and enhancing macrophage
infiltration [13], indicating that CRP might act as a medi-
ator in PVAT inflammation.
On the other hand, CRP could be a potent activator of
angiogenesis. Recent studies showed that the inhibition
of endothelial cell angiogenesis and increased apoptosis
by CRP may be attributed to the presence of sodium azide
in CRP preparations. Slevin et al. [14] reported that CRP
is associated with the formation of immature microvessels
in vivo, which is significantly expressed by stroke neo-
vessels. In vitro, CRP can increase vascular endothelial
growth factor (VEGF)-A expression in bovine aortic endo-
thelial cells, human coronary artery endothelial cells, and
monocytes, which was due to CRP itself but not the
effects of sodium azide and lipopolysaccharide (LPS)
contamination [15–17]. However, whether CRP can also
promote the proliferation and proangiogenic paracrine
activity of adipose-derived stem cells (ADSCs) as an an-
giogenic factor, which contribute to PVAT inflammation-
related vasa vasorum angiogenesis, is still poorly defined.
We hypothesized that human CRP promotes ADSC-
induced angiogenesis in the setting of atherosclerosis. To
test this hypothesis, we investigated the role of CRP on the
proliferation, migration, and paracrine proangiogenic acti-
vity of ADSCs and identified the signaling pathways and
the molecular mechanisms in vitro.
Methods
Mouse ADSC isolation and cell culture
Primary mouse ADSCs from mouse adipose tissue were
isolated and cultured as described previously with minor
modifications [18]. The fatty tissue around the inguinal
region of male C57/BL6 mice, 3–4 weeks old, was sepa-
rated. After the removal of visible blood vessels, lymph
nodes, and fascia, the tissue was finely minced with
scissors and digested with collagenase type I (1.25 % w/v)
for 60 min at 37 °C with gentle shaking. After collagenase
neutralization, the floating adipocytes were separated by
centrifugation at 1200 rpm for 5 min. The resulting pellet
was resuspended and the cells were plated in tissue
culture flasks in Dulbecco’s modified Eagle’s medium with
low glucose (DMEM; Gibco, Thermo Fisher Scientific,
Inc., Waltham, MA, USA) supplemented with 10 % fetal
bovine serum (FBS; Gibco, Thermo Fisher Scientific, Inc.),
100 U/ml penicillin and 0.1 mg/ml streptomycin (both
from Thermo Fisher Scientific, Inc., Waltham, MA, USA),
VEGF 10 ng/ml, basic fibroblast growth factor (FGF)
10 ng/ml, and alpha-FGF 10 ng/ml (Sigma-Aldrich, St.
Louis, MO, USA) at 37 °C in a 5 % CO2 humidified
atmosphere.
Flow cytometry analysis
Cell apoptosis was detected by an Annexin V-FITC
apoptosis detection kit according to the manufacturer’s
instructions. The cells were incubated with or without
the addition of various concentrations of recombinant
human CRP (free of sodium azide; Sino Biological Inc.,
Beijing, China) for different times and then harvested
and rinsed in cold phosphate-buffered saline (PBS). The
fraction of apoptotic cells was determined by cell stai-
ning in Annexin-V binding buffer with FITC-conjugated
Annexin-V and propidium iodide (PI; Sigma-Aldrich).
After 15 min of incubation in the dark at room
temperature, the samples were analyzed by flow cytometry
(LSRII FACS; BD Bioscience, Franklin Lakes, NJ, USA).
Apoptotic cells were identified as Annexin-V-positive
cells.
For the cell cycle analysis, the cells were trypsinized and
fixed in 75 % ethanol for 60 min on ice and stained with
PI and Hoechst 33342 (5 μg/ml; Thermo Fisher Scientific,
Inc.) in PBS for 30 min. Equal numbers of cells were
assessed for ADSCs by flow cytometry analysis.
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Cell proliferation assay
ADSCs were seeded in 96-well plates at a density of 4 × 103
cells/well. After 24, 48, and 72 hours, the medium was
removed and cells were counted using a Cell Counting
Kit-8 (CCK-8; Dojindo, Rockville, MD, USA). Cells were
treated with 10 % CCK-8 solution for 4 hours at 37 °C in a
humidified 5 % CO2 incubator and the absorbance was
measured at 450 nm by a microplate reader.
Cell migration assay
ADSCs were seeded on the upper site of 8.0 μm transwell
membrane plates (Corning, Inc., NY, USA) at a density of
5 × 104 cells per well after serum starvation for 12 hours.
CRP (25 μg/ml) or plus inhibitors (PD098059, 10 μM;
LY294002, 5 μM) in DMEM were introduced on the
lower site of transwell membrane plates for 12–24 hours.
Migrated cells remaining in the transwell membrane were
fixed and then stained using 10 % crystal-violet (Sigma-
Aldrich), and cells in the membrane were counted by
light microscopy.
Inhibitor and block antibody treatment
After reaching 80 % confluence, ADSCs were seeded in
six-well plates (5 × 105 cells/well). The cells were treated
with the following reagents for 24 hours: (a) ADSC
basal medium as a control; (b) stimulant CRP alone; (c)
stimulant plus inhibitors or block antibodies, including
ERK inhibitor (PD098059, 10 μM), PI3K inhibitor (LY29
4002, 5 μM), and nuclear factor-kappa beta (NF-kB)
inhibitor (BAY-11-7082, 5 μM) (all from Cell Signaling
Technology, Danvers, MA, USA), or anti-CD16 (2 μg/ml;
R&D Systems, Inc., Madison, WI, USA), anti-CD16/32
(1 μg/ml; Abcam Inc., Cambridge, UK), and anti-CD64
(1:100, 3 μg/ml; R&D Systems Inc.); or (d) inhibitors
and block antibodies alone. Doses of the inhibitors or
block antibodies were determined according to previous
laboratory characterization and published data. Superna-
tants and cell extractions were collected 24 hours after
treatment.
In-vitro tube formation assay
Tube formation on Matrigel was performed as described
previously [19]. A total of 50 μl of chilled Matrigel (BD
Bioscience) was added to a 96-well plate and incubated
at 37 °C for 30 min. Human umbilical vein endothelial
cells (HUVECs; 1 × 104 cells) were suspended in 100 μl
of EBM-2 or endothelial growth medium (EGM; LONZA
Inc., Basel, Switzerland), and conditioning medium (CM)
of ADSCs, CRP-treated CM of ADSCs or plus VEGF-neu-
tralizing antibody (0.15 μg/ml; R&D Systems Inc.), or
EBM-2 plus CRP was added to the solidified Matrigel. The
CM was harvested after incubation of the ADSCs in EBM-
2 for 24 hours. After incubation on Matrigel at 37 °C in a
5 % CO2 chamber, morphological changes were observed
under a microscope (Leica, Germany). The five representa-
tive fields were photographed. Images were analyzed using
Image J software (NIH, Bethesda, MD, USA) to determine
the tube lengths.
In-vivo Matrigel plug assay
The animal experiments were conducted according to the
guidelines and ethical standards of the Animal Care and
Use Ethics Committees of Sun Yat-Sen University
(IACUC-DB-16-070). ADSC (100 μl, 1 × 106 cells) or
CRP-treated ADSC (24-hour pretreatment with 25 μg/ml
CRP without FBS, 1 × 106 cells) suspensions were mixed
with 400 μl of ice-cold growth factor reduced phenol red-
free Matrigel (BD Bioscience), and Matrigel containing
PBS was used as a negative control. The Matrigel mixture
was injected subcutaneously into the dorsal area of male
nu/nu mice, 4–5 weeks old. Each experimental condition
was performed with three mice. At day 7, the Matrigel
implants were removed and then fixed with formalin, and
the fixed Matrigel plug was embedded in paraffin to
prepare sections for hematoxylin and eosin (H & E).
Enzyme-linked immunosorbent assay
The assay was performed for the CM using a mouse angio-
genesis array kit (R&D Systems, Inc.) according to the man-
ufacturer’s instructions. VEGF-A production was examined
by enzyme-linked immunosorbent assay (ELISA) using a
commercially available kit (Raybiotech, Atlanta, GA, USA)
according to the manufacturer’s instructions.
Western blot analysis
To prepare the protein extracts, the cells were rinsed twice
with ice-cold PBS and harvested. After centrifugation,
the cells were resuspended and extracted in lysis buffer
(Thermo Fisher Scientific, Inc.) for 30 min on ice. Protein
concentrations were assayed using Pierce Coomassie Plus
reagent according to the manufacturer’s instructions, and
40 μg of protein was loaded for separation by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE). The proteins were then transferred to polyviny-
lidene difluoride membranes (Immobilon-P; EMD Milli-
pore Corporation, Billerica, MA, USA). The membranes
were blocked in Tris-buffered saline containing 5 % bovine
serum antigen (BSA) and probed with HIF-1a, tissue inhibi-
tor of metalloproteinase-2 (TIMP-2), VEGF-A, hepatocyte
growth factor (HGF), matrix metalloproteinase (MMP)-2,
and MMP-9 (all from R&D Systems Inc.) corresponding
antibodies. Reacted bands were detected by horseradish
peroxidase-conjugated secondary antibodies and enhanced
chemiluminescence substrates (PerkinElmer, Boston, MA,
USA).
Chen et al. Stem Cell Research & Therapy  (2016) 7:114 Page 3 of 13
Quantitative real-time PCR
Total RNA was extracted using Trizol reagent (Thermo
Fisher Scientific, Inc.). The synthesis of cDNA was per-
formed on DNaseI-treated total RNA templates (0.5 μg)
using an iscript™ cDNA synthesis kit. Gene expression was
assessed by quantitative real-time PCR (qRT-PCR) using
SYBR Green intercalating dye (Thermo Fisher Scientific,
Inc.) and mouse primers. The primer sequences are pre-
sented in Additional file 1: Table S1. The comparative
threshold cycle method was used to calculate the ampli-
fication fold as specified by the manufacturer. The ampli-
fied PCR products were separated by gel electrophoresis
in a 2 % agarose gel visualized with ethidium bromide.
Each sample was replicated at least three times.
Immunofluorescence staining
The ADSCs were fixed with 4 % paraformaldehyde (PFA)
for 10 min, followed by blocking with 5 % BSA in PBS for
60 min at room temperature. The cells were incubated with
the following antibodies at room temperature for 1 hour:
rabbit anti-CD16/32 (1:200; Abcam Inc.) and rabbit anti-
CD64 (1:200; Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA). Following a wash in PBS, the cells were incu-
bated in goat anti-rabbit secondary antibodies conjugated
with FITC (1:200; Thermo Fisher Scientific, Inc.) in PBS for
1 hour at room temperature. DAPI was used for the
nuclear stain. The samples were then washed three times,
and mounted in mounting medium (Vector Laboratories,
Burlington, CA, USA). Images were obtained using an
inverted fluorescence microscope.
Immunoprecipitation
The ADSCs were incubated with CRP (25 μg/ml) for
6 hours and then washed and lysed in 1 ml of RIPA
buffer. Cell lysates were precipitated with goat antibodies
against CRP (2 μg per 100 g of total protein; Santa Cruz
Biotechnology, Inc.) that had been preabsorbed by
protein G-Sepharose (Biotool Inc., Houston, TX, USA).
Immunoprecipitated proteins were washed in RIPA
buffer, subjected to SDS-PAGE, and immunoblotted with
specific antibodies against CRP (Santa Cruz Biotechno-
logy, Inc.) or FcgRs (1:200; R&D Systems, Inc.).
Statistical analysis
The in-vitro data are representative of independent exper-
iments performed in triplicate. The statistical analysis was
conducted using SPSS software (SPSS, Inc., Chicago, IL,
USA). The statistical significance of the differences among
groups was tested using one-way analysis of variance or
Student’s t test. Error bars are indicative of standard devi-
ation. p < 0.05 or p < 0.01 was considered significant.
Results
Characterization of ADSCs
In this study, we isolated ADSCs from the mouse adi-
pose tissue; the isolated cells were plastic adherent and
exhibited spindle-like morphology with a whirlpool-like,
colony-forming unit (CFU) of ADSCs (Additional file 1:
Figure S1B1, B2). The cells were positive for mesenchy-
mal markers (CD29, CD44, CD90, and SCA-1), and were
negative for endothelial (CD105 and CD31), pericyte
(CD146), and hematopoietic (TER-119, CD45) markers
(Additional file 1: Figure S1A). In addition, the cells were
able to differentiate into mesenchymal lineage cells such
as adipocytes and osteocytes (Additional file 1: Figure
S1B3, B4). Thus, we confirmed that the cells derived from
adipose tissue have typical MSC characteristics.
CRP did not affect ADSC apoptosis or proliferation but
increased migration via the PI3K/Akt signaling pathway
Several previous studies demonstrated that CRP was asso-
ciated with cell proliferation and apoptosis in endothelial
cells, endothelial progenitor cells, renal tubular epithelial
cells, and myeloma cells [20, 21], but this is the first study
to investigate the effect of CRP on ADSC proliferation
and apoptosis. We found that CRP (0–100 μg/ml) treat-
ment had no significant effects on ADSC proliferation at
24, 48, and 72 hours using a CCK-8 assay (Fig. 1a). CRP
treatment slightly increased ADSC migration in a cham-
ber migration assay, which was significantly suppressed by
Akt inhibitor (LY294002) treatment (Fig. 1c), indicating
that CRP increases ADSC migration via the PI3K/Akt
signaling pathway. Our results also showed that CRP treat-
ment did not induce ADSC apoptosis even in the presence
of CRP at higher concentrations (100 mg/ml) by Annexin-
V binding analysis (data not shown), suggesting that CRP
might play a different role in ADSC apoptosis induction.
Because cell cycle mechanisms control stem cell prolife-
ration under normal conditions and stem cells generally
remain in the quiescent G0 phase in vivo, further investiga-
tions were performed to determine whether CRP affected
cell cycle regulation by staining with PI and Hoechst 33342.
No significant difference was observed between any two
groups at different CRP concentrations (0–100 μg/ml) in
the distribution of each phase of the cell cycle (Fig. 1b),
which is consistent with its function in ADSC proliferation.
CRP treatment upregulates VEGF-A protein and
production in ADSCs
A recent study demonstrated that CRP preparations might
have been contaminated by bacterial endotoxin bypro-
ducts and that LPS (200 ng/ml) could promote VEGF-A
production in bone marrow-derived mesenchymal stem
cells (BMSC) [22]. Accordingly, when we examined the
changes of VEGF-A and HGF expression in ADSCs after
CRP treatment at different concentrations (0–50 μg/ml)
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respectively by western blotting and ELISA, we should
exclude the effect of LPS potentially present in the CRP
preparations. From the results we found that the VEGF-A
protein levels were increased after CRP treatment in a
dose-dependent manner (Fig. 2a), whereas the HGF pro-
tein levels were not. We found that CRP increased VEGF
production in ADSCs in a dose-dependent and time-
dependent manner (Fig. 2b). VEGF-A protein expression
and production was not abrogated by preincubation with
polymyxin B (5 μg/ml), which is used to exclude the
effect of LPS potentially present in CRP preparations (data
not shown). Also CRP 25 μg/ml did not have a significant
effect on adipogenic and osteogenic differentiation (Add-
itional file 1: Figure S2).
CRP-induced VEGF-A upregulation promotes angiogenesis
in ADSCs
We then examined the functions of CRP-induced VEGF-
A in angiogenesis, and the results demonstrated that
HUVECs can form more tubes in ADSC growth medium
than in basal medium. In addition, tube length was
significantly increased in the CRP-treated ADSC super-
natant compared with the normal ADSC supernatant but
decreased compared with EGM. This induction effect of
CRP can be significantly inhibited by VEGF-neutralizing
antibody treatment (Fig. 2c). To further investigate whether
CRP promotes ADSC-induced angiogenesis in vivo, the
Matrigel plug assay was performed in nu/nu mice. Our
results demonstrated that CRP-treated ADSC Matrigel
implants showed more functional vessels containing eryth-
rocytes than untreated ADSCs (Fig. 2d). Furthermore, we
compared the expression levels of angiogenesis-related
proteins in the condition medium (CM) of ADSCs with or
without CRP treatment using a commercial antibody assay.
Among 55 angiogenesis-related proteins, the expression
levels of five were upregulated after CRP treatment—osteo-
pontin, SDF-1, MCP-1, VEGF, and proliferin (Fig. 3)—which
are reportedly associated with endothelial cell proliferation,
migration, and/or tube formation in vitro.
CRP promotes MMP-2 proteolytic activity in ADSCs
MMP family members and their suppressor TIMP are the
dominant factors in transformation of the extracellular
matrix (ECM), which is closely related to angiogenesis, so
we determined the levels of MMP and TIMP with CRP
treatment in ADSCs. Firstly, quantitative determination of
Fig. 1 CRP did not affect ADSC apoptosis or proliferation but slightly increased migration via the PI3K/Akt pathway. a Proliferation determined by a
CCK-8 assay of ADSC cultures 24, 48, and 72 hours after addition of CRP. b Distribution of the cell cycle phase of ADSCs in 24-hour cultures with or
without CRP treatment. c CRP increased the migration of ADSCs and inhibition of Akt (LY294002) significantly inhibited ADSC migration. Data represent
mean ± SE (n = 3). Columns, mean; error bars, SEM; *p < 0.05. Results are representative of three independent experiments. CRP C-reactive protein, FBS
fetal bovine serum, OD optical density
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Fig. 2 (See legend on next page.)
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mRNA expression in ADSCs by RT-PCR revealed the
transcription levels of MMPs and TIMPs compared with
that of GAPDH. The expression of MMP-2 mRNA was
higher than that of MMP-9, MT2-MMP and MT3-MMP
mRNA, whereas MT1-MMP and TIMP-4 mRNA expres-
sion was undetectable (Fig. 4a). Moreover, our results
showed that CRP treatment can increase MMP-9 mRNA
and protein levels in a dose-dependent manner (Fig. 4b,
c), but interestingly no MMP-9 activity was found in the
supernatant of untreated or CRP-treated ADSCs, which
meant MMP-9 activity might be totally suppressed by
high-level secretion of TIMP-1 in ADSCs (Fig. 3). Because
MMP-2 activity is regulated by MMP-2, TIMP-2, and
MT-MMPs in stem cells [23], we next examined the
effects of CRP treatment on MMP-2, TIMP-2, and
MT-MMP levels. Both qRT-PCR assay and western blot
analysis indicated that CRP significantly increased the
mRNA and protein expressions of MMP-2 and TIMP-2,
but had no effect on the expression of MT2-MMP and
MT3-MMP (Fig. 4b, c). We also found that CRP induced
MMP-2 proteolytic activity in the supernatant of ADSCs
in a dose-dependent manner using gelatin zymography
(Fig. 4d). All evidence suggests that MMP-2 proteolytic
activity might be further evidence for CRP-mediated angio-
genesis in ADSCs.
CRP upregulates VEGF-A expression by activating HIF-1α
via the PI3K/Akt and MAPK/ERK signaling pathways in
ADSCs
It was observed that CRP treatment can remarkably
induce ERK, Akt, and NF-kB phosphorylation (Fig. 5a).
Then we found that the coincubation of cells with CRP
and their pharmacological inhibitors of the MAPK path-
way (PD98059) or the PI3K/AKT pathway (LY294002)
could abrogate the effects of CRP-mediated phosphory-
lated kinases examined by WB or upregulation of VEGF-A
production examined by ELISA in ADSCs, and cyclohexi-
mide, a protein expression inhibitor, reduced the increased
VEGF-A production induced by CRP (Fig. 5b). However,
no detectable difference was observed with or without the
coincubation of NK-kB inhibitor (BAY-11-7082) (Fig. 5c).
Next, we further explored how CRP induced VEGF
expression in transcriptional regulation. Regarding the
amount of transcription factors such as HIF-1α, AP1, NF-
(See figure on previous page.)
Fig. 2 CRP treatment upregulates VEGF protein and production levels and promotes angiogenesis in ADSCs. a CRP increased VEGF but not HGF
production as assessed by western blotting. Values were normalized to β-tubulin as a control, *p< 0.05 versus control. b CRP increased VEGF production
dose and time dependently as assessed by ELISA, peak at CRP 25 μg/ml, *p< 0.05 versus control. c CRP-induced VEGF increased capillary tube formation in
vitro. (C1) HUVECs formed tubes in basal medium; (C2) culturing of HUVECs in ADSC supernatant induced tube formation; (C3) CRP-treated ADSCs
conditioned medium (CM) enhanced tube formation; (C4) CRP-treated basal medium slightly decreased the HUVEC tube formation; (C5) HUVECs formed
tubes cultured in EGM as positive control; (C6) VEGF-neutralizing antibody in CRP-treated ADSC CM prevented HUVEC tube formation; (C7) representative
histogram of tube length in different medium, *p< 0.05, **p< 0.01. d Mice were injected subcutaneously with Matrigel mixed with PBS, ADSCs, and
CRP-pretreated ADSCs. At day 7, mice were sacrificed, explanted Matrigel plugs were excised and processed for H & E staining (upper bars 100 μm,
lower bars 50 μm) and light microscope, and microvessel density was quantified by counting vessel structures containing erythrocytes. Representative
histogram of tube length in different medium, *p< 0.05; data represent mean ± SEM (n= 3). Columns, mean; error bars, SEM. Results are representative
of three independent experiments. CRP C-reactive protein, VEGF vascular endothelial growth factor, HGF hepatocyte growth factor, ADSC, adipose-derived
stem cell, EGM endothelial growth medium, MSCmesenchymal stem cell
Fig. 3 CM with or without added CRP analyzed by antibody-based protein arrays. ADSCs were cultured with 10 % FBS low-glucose DMEM until
80–90 % confluence was reached and then incubated in DMEM for 24 hours. The CM was then collected for protein assays; increased proteins after
CRP treatment are indicated with letters. CRP C-reactive protein, VEGF vascular endothelial growth factor
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kB, and SP1, HIF-1α is most closely related to VEGF
regulation in stem cells. Our results showed that CRP
treatment can increase HIF-1α protein expression levels
in the nucleus (Fig. 6a). In contrast, further western blot
analysis showed that CRP-induced regulation of HIF-1α
and VEGF-A protein expression can be suppressed by
HIF-1α inhibitor treatment (2-methoxyestradiol, 10 μM)
(Fig. 6b), suggesting that CRP may promote HIF-1α to
enter the nucleus to induce VEGF expression in ADSCs.
Furthermore, our results also showed that ERK and Akt
inhibition can suppress CRP-stimulated HIF-1α and VEGF-
A protein expression (Fig. 6c), indicating that CRP-induced
MAPK/ERK and PI3K/AKT pathway activations were
related to HIF-1α activation of VEGF expression in ADSCs.
CD64 mediated CRP-induced VEGF expression regulation
in ADSCs
To understand how CRP acts on ADSCs, further studies
were designed to reveal the way in which CRP binds to the
ADSC membrane surface receptor. It is well known that
CRP shares several functional properties with immuno-
globulin G and binds to FcgRs, which are designated Fc
gamma RI (also known as CD64), Fc gamma RII (CD32),
and Fc gamma RIII (CD16). The findings of RT-PCR and
immunofluorescence staining indicated that CD16/32 and
CD64 were expressed in ADSCs (Fig. 7a, b). We found that
CRP stimulation resulted in increased expression of CD64
mRNA in ADSCs, whereas the CD16 and CD32 mRNA
levels showed no significant changes (Fig. 7c). We then
Fig. 4 CRP promotes MMP-2 proteolytic activity in ADSCs. a RT-PCR analysis of MMP-2, MMP-9, MT2-MMP, MT3-MMP, TIMP-2, TIMP-3, and TIMP-4 gene
transcription in ADSCs. Results are mean values ± SD of mRNA expression relative to GAPDH. b mRNA expression of MMPs and TIMPs quantified by
RT-PCR after 24 hours of incubation with CRP (25 μg/ml) under serum-free conditions. Results given as the fold change in mRNA expression relative
to untreated cells set as 1, *p < 0.05, versus control. c, e, f, g CRP significantly increased the gene and protein expression of MMP-2, MMP-9 and TIMP-2.
d CRP induced MMP-2 proteolytic activity in ADSCs, but MMP-9 proteolytic activity was undetected. *p < 0.05, **p < 0.01 versus control; data represent
mean ± SE (n = 3). Columns, mean; error bars, SEM. Results are representative of three independent experiments. MMP matrix metalloproteinase, TIMP
tissue inhibitor of metalloproteinase, CRP C-reactive protein
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examined the roles of CD16, CD32, and CD64 in CRP-
regulated VEGF production in ADSCs. Interestingly, spe-
cific blocking antibodies for both CD16 and CD16/32 had
no significant effects on VEGF-A expression after CRP
stimulation in ADSCs, whereas CD64-neutralizing anti-
body partially abrogated the effect of CRP treatment
(Fig. 7d). Furthermore, immunoprecipitation with mono-
clonal antibodies (mAbs) against CRP was performed to
examine whether and which FcgRs bind to CRP on
ADSCs. We found that mAbs against CRP can precipitate
CD64 but not CD16/32 (Fig. 7e), suggesting that CRP-
regulated VEGF expression is CD64 dependent.
Discussion
Mesenchymal stem cell-induced angiogenesis was found
to be regulated mainly by proangiogenic paracrine acti-
vity, such as high-level secretions of VEGF, HGF, FGF,
and insulin-like growth factor (IGF) [24, 25], which can
promote angiogenesis through stimulating endothelial
cell maturity, migration, and proliferation. Among these
Fig. 5 CRP induces phosphorylation of ERK and Akt, and inhibiting both pathways abrogated the increasing of VEGF production. a, b CRP induced
phosphorylation of ERK, Akt, and NF-kB; the effect peaked at 120 min. Pharmacological inhibitors of MAPK (PD98059), PI3K/AKT (LY294002), and NF-ĸB
(BAY-11-7082) inhibited the CRP-mediated increase of phosphorylated kinases. LY249002 (10 μM) for PI3K-specific inhibitor, PD98059 (10 μM) for MAPK
inhibitor, BAY-11-7082 (10 μM) for inhibitor for NF-ĸB. Inhibitor concentrations were chosen based on the manufacturer’s recommendations and our
preliminary experimental findings. c Effects of kinase inhibitors on CRP-induced VEGF production examined by ELISA. Inhibition of the MAPK and
PI3K/AKT signaling pathways but not NF-ĸB/IkBα and cycloheximide partly abrogated the increased CRP-induced VEGF production. Columns, mean;
bars, SE. *p < 0.05. The results are representative of three independent experiments. CRP C-reactive protein, VEGF vascular endothelial growth factor
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angiogenic factors, VEGF plays a key role in angiogen-
esis. VEGF secretion levels in ADSCs are low in cultured
conditions, our results indicating that CRP can upregu-
late VEGF expression and production in ADSCs, which
significantly increased endothelial cell tube formation in
Matrigel, and that CRP pretreated ADSCs formed more
functional vessels in vivo. As we know, MMPs play an
important role in the formation and maintenance of new
capillaries in vivo and in vitro. Previous studies showed
that MMP-2 and MMP-9 were involved in coronary artery
wall formation in experimental hypercholesterolemia,
which coincides with vasa vasorum neovascularization
[26]. We found that the addition of CRP significantly
increased MMP-2 activity in a dose-dependent manner. In
addition, we found CRP had no significant influence
on the expression of inflammatory cytokines in ADSCs
determined by RT-PCR, such as IL-10, IL-6 and IL-1β
(Additional file 1: Figure S3), indicating that CRP-induced
angiogenesis in ADSCs may not be driven by inflamma-
tory response. All of this evidence indicates that CRP can
increase VEGF production and MMP-2 activity in ADSCs,
which triggers endothelial cell activation and accelerates
ECM degradation to play a substantial role in subsequent
vasa vasorum proliferation.
To further explore the mechanisms of CRP-induced
VEGF expression levels, we also examined the activation
of HIF-1α, an important transcription factor that regulates
VEGF expression via the binding of hypoxia-response
Fig. 6 CRP stimulated VEGF expression through HIF-1α, which was linked to activation of the PI3K/AKT1 and MAPK/ERK1/2 pathways. a CRP increased
HIF-1α production as assessed by western blotting. b HIF-1α inhibitor (2-methoxyestradiol, 10 μM) prevented CRP-induced HIF-1α and VEGF protein
expression. c Effects of kinase inhibitors on CRP-induced HIF-1α and VEGF expression examined by western blotting. MAPK and PI3K signaling pathway
inhibition suppressed CRP-induced HIF-1α and VEGF expression. Columns, mean; bars, SE. *p < 0.05. Results are representative of three independent
experiments. CRP C-reactive protein, VEGF, vascular endothelial growth factor, HIF-1α hypoxia inducible factor-1α, PCNA, proliferating cell nuclear antigen
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element (HRE) sites in the VEGF promoters in stem cells
[27, 28] after ADSC CRP treatment. In normoxic condi-
tions, HIF-1 is upregulated by growth factors, cytokines,
hormones, and deregulated oncogenes. Our results indi-
cated that CRP can increase HIF-1α protein expression
in the nucleus of ADSCs. Moreover, CRP-mediated VEGF
and HIF-1α expression changes can be abrogated by HIF-
1α inhibitor (2-methoxyestradiol), which can depolymerize
the microtubules and inhibit HIF-1α nuclear accumulation
and transcriptional activity, indicating that CRP promoted
ADSC VEGF production via activating HIF-1α.
Since HIF prolyl hydroxylases (PHDs) regulate HIF-1
during hypoxia conditions, the PI3K/Akt and MAPK/
ERK pathways mediate primarily nonhypoxic HIF-1 and
VEGF regulation [29]. Firstly, our results showed that
CRP can induce the PI3KAkt, MAPK/ERK1/2, and NF-
kB/IkBα signaling pathways. As we know, IkBα phos-
phorylation can activate NF-kB (another VEGF transcrip-
tion factor) to release it from IkBα complex and bind to
HRE sites in VEGF promoters in the nucleus. In the
present study, however, only inhibiting the MAPK/ERK
and PI3K/Akt pathways, but not the NF-kB pathway,
could abrogate CRP-induced VEGF production, which
is consistent with the other previous studies [30–32]. Our
results further showed that ERK and Akt inhibition can
suppress CRP-stimulated HIF-1α and VEGF protein
expression, which means that CRP stimulated VEGF
expression through HIF-1α in ADSCs was linked to the
activation of canonic pathways (PI3K/AKT1 and MAPK/
ERK1/2) (see Fig. 8).
Fig. 7 CD64 mediated CRP-induced VEGF expression regulation in ADSCs. a Immunofluorescence staining of ADSCs for FcγRIII (CD16), FcγRII (CD32),
and FcγRI (CD64) expression in ADSCs. b mRNA expression of CD16, CD32, and CD64 detected by PCR amplification and agarose gel electrophoresis.
c CRP stimulation significantly increased CD64 mRNA expression in ADSCs, whereas no significant difference was detected in CD16 and CD32,
*p < 0.05, versus control. d Effects of CD16, CD16/32, and CD64 blocking antibody on CRP-stimulated (25 μg/ml) VEGF production in ADSCs in
which CD64-neutralizing antibody partly abrogated the effect of CRP. e Immunoprecipitation (IP) using antibodies against CRP in ADSCs treated
with or without CRP (25 μg/ml). Blotting antibodies were against CRP or FcgRI, *p < 0.05. Columns, mean; bars, SEM. Results are representative of
three independent experiments. CRP C-reactive protein, VEGF, vascular endothelial growth factor, HIF-1α hypoxia inducible factor-1α, WB, western blot
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CRP can bind to Fcr receptors (FcgRs), which lead to in-
direct (via classical complement) and direct opsonization
(via FcrRs). We found that ADSCs expressed FcgRs, which
are also expressed by many kinds of cell types; for ex-
ample, immune, endothelial, smooth muscle, and tubular
epithelial cells [20, 33]. Blocking FcgRI can partially abro-
gate CRP-stimulated VEGF production, and CRP can bind
and precipitate CD64 on ADSCs. Compared with CD16/
32, CD64 displays higher affinity to CRP and modulates
its actions within immune response cells [34]. This evi-
dence suggested that FcgRI might serve as the major CRP
receptor in ADSCs and as a novel therapeutic target for
preventing CRP-induced ADSC angiogenesis in the in-
flammatory condition.
Conclusion
Our results showed that CRP had no significant effects on
ADSC apoptosis and proliferation, whereas it increased
ADSC migration via the PI3K/Akt signaling pathway. CRP
also significantly stimulated VEGF production, mainly by
activating HIF-1α via the CD64/PI3K/Akt and MAPK/
ERK signal transduction pathways, and increased MMP-2
activity in ADSCs. Our findings will provide new evidence
that CRP could promote growth of the vasa vasorum in
atherosclerosis.
Highlights
1. Previous studies about CRP-induced atherosclerosis
mostly focused on the intima and medium, such
as the effect of CRP on endothelial cells, SMC,
mononuclear cells, and so forth. For the first time,
we hypothesized that CRP may play an important
role in the development of atherosclerosis by
promoting mesenchymal stem cell angiogenesis in
periadventitial adipose tissue, and we found that
CRP can promote ADSC-induced angiogenesis by
stimulating VEGF expression and increasing the
activity of MMP-2 in vitro, providing new evidence
for CRP as a cardiovascular risk factor.
2. For the first time, we found that CRP binds
activating CD64 on ADSCs, rather than CD16/32.
CD64 may act as a novel therapeutic target for
preventing CRP-induced ADSC angiogenesis in
the inflammatory condition.
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